Helicobacter pylori-induced inflammation masks the underlying presence of low-grade dysplasia on gastric lesions

Table 1 Baseline demographic and clinical characteristics of patients who underwent Helicobacter pylori eradication

Parameters	Patients (n = 85)
Age, mean (SD), yr	56.1 (12.3)
Gender, n (%)
Female	53 (62.4)
BMI, mean (SD), kg/m2	25.1 (2.2)
Alcohol users (12-24 g/dL /die), n (%)	27 (31.8)
Previous smokers, n (%)	12 (14.1)
Drug users, n (%)	23 (27.1)
Family history of gastric cancer, n (%)	4 (4.7)
Family history of other cancer, n (%)	9 (10.6)
Autoimmune comorbidity
Autoimmune atrophic gastritis	12 (14.1)
Autoimmune thyroiditis	6 (7.1)
Type-1/2 diabetes mellitus	3 (3.5)
Skin psoriasis	1 (1.2)
Rheumatoid arthritis	1 (1.2)
Sjögren syndrome	1 (1.2)
A. thyroiditis + vitiligo	1 (1.2)
A. thyroiditis + Crohn’s disease	1 (1.2)
A. thyroiditis + Sjögren syndrome	1 (1.2)
APCA and/or AIF antibody positivity	12 (14.1)
Endoscopy indication, n (%)
Gastroesophageal reflux	17 (20)
Recurrent abdominal pain	12 (14.1)
Dyspepsia	41 (48.2)
Unexplained anemia	15 (17.7)
H. pylori eradication scheme, n (%)
Quadruple1	53 (62.4)
Modified triple2	28 (32.9)
Triple3	3 (3.6)
Sequential4	1 (1.2)
H. pylori eradication cycles, n (%)
One-cycle	71 (83.5)
Two-cycles	14 (16.5)

Data are expressed as number of patients and percentage (in parenthesis).

¹Bismuth + Metronidazole + Tetracycline + Proton pump inhibitor.

²Amoxicillin + Levofloxacin + Proton pump inhibitor.

³Amoxicillin + Clarithromycin + Proton pump inhibitor.

⁴Amoxicillin + Clarithromycin + Proton pump inhibitor Amoxicillin (5 d), then Clarithromycin + Metronidazole (5 d) + Proton pump inhibitor. BMI: Body mass index; SD: Standard deviation; APCA: Anti-parietal cell antibody; AIF: Anti-intrinsic factor; H. pylori: Helicobacter pylori; PPI: Proton pump inhibitor.